The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer (Q34791139)

4 August 2017

1 reference

title

The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer (English)

1 reference

4 August 2017

2

Ulrich Andergassen

0 references

Matthias W. Beckmann

9

object named as

Matthias W Beckmann

1 reference

4 August 2017

8

Klaus Friese

1 reference

4 August 2017

6

0 references

author name string

Brigitte Rack

1

1 reference

4 August 2017

Julia Neugebauer

3

1 reference

4 August 2017

Jessica Salmen

4

1 reference

4 August 2017

Philip Hepp

5

1 reference

4 August 2017

Werner Lichtenegger

7

1 reference

4 August 2017

Dagmar Hauner

10

1 reference

4 August 2017

Hans Hauner

11

1 reference

4 August 2017

Wolfgang Janni

12

1 reference

4 August 2017

8 December 2010

1 reference

4 August 2017

1 reference

4 August 2017

5

1 reference

4 August 2017

395-400

1 reference

4 August 2017

6

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Obesity and weight change in relation to breast cancer survival.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Anthracycline cardiotoxicity: from bench to bedside

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Cardiac toxicity in breast cancer survivors: review of potential cardiac problems.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Physical Activity and Survival After Breast Cancer Diagnosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Weight loss in breast cancer patient management

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Obesity and hormone therapy in breast cancer: an unfinished puzzle

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Long-term recreational physical activity and risk of invasive and in situ breast cancer: the California teachers study

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3076352

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

26 October 2018

1 reference

12 December 2020

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results

1 reference

12 December 2020

Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International

1 reference

12 December 2020

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Identifiers

DOI

10.1159/000322677

1 reference

4 August 2017

1 reference

4 August 2017

1 reference